Australia has emerged as one of the most active peptide-regulatory jurisdictions outside the United States. The Therapeutic Goods Administration (TGA) first issued a public safety advisory on unapproved peptides in April 2026 — joining the UK MHRA and Health Canada in a coordinated global tightening of the gray-market peptide channel — then escalated in June 2026 by formally designating unapproved peptides a compliance priority.
The TGA's June 2026 escalation cited rising importation, expanding online advertising, and hospitalisation data identifying serious adverse effects associated with products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295. An eight-month operation involving the TGA, Australian Border Force, and Victoria Police seized about $2M worth of peptides, performance-enhancing drugs, and illicit steroids. Future compliance actions may include infringement notices, product seizures, import interventions, and civil or criminal penalties; advertising or promoting unapproved peptides through social media or influencer channels is likely to breach Australian therapeutic goods advertising laws.
Stories here cover TGA enforcement actions, Australian-market access decisions for approved peptide therapies (Wegovy, Mounjaro on PBS), and the broader Australia-Pacific regulatory picture. See #tga, #unapproved-peptides, and #gray-market for adjacent threads.
Australia's Therapeutic Goods Administration has cleared Lilly's daily Foundayo pill for weight management and type 2 diabetes, 7NEWS reported on November 17 Australian time, weeks after the Wegovy pill was approved. It is available by private prescription but not yet listed on the Pharmaceutical Benefits Scheme, and Lilly Australia said trials enrolled more than 10,000 patients in 15 countries. Associate Professor Samantha Hocking said obesity and overweight now affect around 13 million Australian adults.
Hepatitis Australia and the Australasian Society for Infectious Diseases urged people injecting peptides to use new sterile equipment every time, citing Kirby Institute data showing that the share of needle-exchange visits tied to anabolic agents and hormones rose from 9% in 2022 to 14% in 2025, Medical Republic reported. Days earlier, TGA lab testing found no TB-500 in three Synedica products labeled with it, including the KLOW and BARBIE KLOW blends, and less retatrutide than stated in Synedica Retatrutide 10 mg.
Adelaide influencer Josh Sawyer, 22, told ABC News he earned up to A$2,000 a week in commission while affiliated with Vital Peptides Australia, which sold GHK-Cu and other unapproved peptides; the European testing lab Janoshik confirmed that certificates of analysis displayed by the seller had been altered, and Vital did not respond to the ABC. The Australian Poisons Information Centre recorded 345 poisoning-related cases involving unapproved peptides in the first six months of 2026, more than three times its total for 2025, and the TGA says it has seized and destroyed more than 94,500 unapproved peptide products this year.
Former St George Illawarra Dragons and State of Origin player Trent Merrin, 37, was charged on Tuesday, November 3, with four counts of manufacturing goods for use in humans resulting in harm or injury and one count of participating in a criminal group, ABC News reported. The charges follow a July 24 raid in which an Organised Crime Squad strike force working with the Therapeutic Goods Administration allegedly found a clandestine peptide manufacturing facility and large quantities of restricted substances; a 39-year-old man charged in August has had his case finalised. Merrin's solicitor said he will plead not guilty, and he is due in Wollongong Local Court on November 24.
The Therapeutic Goods Administration approved Novo Nordisk's oral semaglutide tablet on Tuesday, November 3, in 1.5, 4, 9, and 25 mg strengths for adults with obesity and for lowering cardiovascular risk, ABC News reported. The TGA still has to review packaging and production before the pill can be released, no price has been set, and under current rules the Pharmaceutical Benefits Scheme subsidizes these drugs only for type 2 diabetes. Eli Lilly's orforglipron is still awaiting a TGA decision.
After a Victorian coroner linked actor Richard Norton's death to injected CJC-1295 and ipamorelin, independent MP Dr Monique Ryan renewed her call for the Health Minister to refer telehealth and online prescribing to the House Health Committee, Retail Pharmacy reported. She first wrote to the minister in August; the inquiry she wants would examine companies that combine telehealth, pharmacy, and retail, the routes that let unapproved peptides be prescribed and compounded, and gaps between the TGA, AHPRA, and the states. "This inquiry is about protecting good telehealth from profit-driven prescribing, not winding it back," she said.
ABC News reported that Victorian coroner David Ryan found Richard Norton, 75, died at Melbourne's Alfred Hospital on March 30, 2025, from complications of injecting the unapproved peptides CJC-1295 and ipamorelin, which a licensed Queensland compounding pharmacy made for him. Norton had told a clinic nurse he was injecting double his prescribed dose and collapsed hours later after another injection. Ryan recommended the Therapeutic Goods Administration review the peptides' benefits and risks and consider further restrictions; the ABC called it believed to be Australia's first confirmed death from unapproved peptide use.
New South Wales Health Minister Ryan Park warned on October 19, 2026 that 1,180 people attended NSW emergency departments after taking unapproved peptides between July 2025 and September 2026, with monthly presentations rising from 5 to almost 220, ABC News reported. NSW Health said unapproved products may contain BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295, and Park cited liver and kidney damage, allergic reactions, and severe vomiting. He urged people to use only peptides prescribed by a doctor and dispensed by a pharmacy, and said the issue would likely go to other Australian health ministers.
Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update Saturday July 25, 2026 for GLP-1 receptor agonists on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. The label update applies across all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that the current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A search of the Australian Database of Adverse Event Notifications (DAEN) found 36 cases of optic ischaemic neuropathy with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patient guidance advises seeking urgent medical attention for any sudden vision loss including partial loss of vision. The Australian action follows the UK MHRA Drug Safety Update on semaglutide and NAION issued February 5, 2026.
Australia's Therapeutic Goods Administration (TGA) escalated its peptide-products oversight to a formal compliance priority in a June 2026 media release, citing rising importation, expanding online advertising and supply, and hospitalisation data identifying serious adverse effects associated with unapproved peptides. Targeted products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295. The TGA emphasized that unapproved peptide products are not in the Australian Register of Therapeutic Goods and have not been evaluated for safety, quality, or efficacy. An eight-month operation involving TGA, the Australian Border Force, and Victoria Police seized about $2M worth of peptides, performance-enhancing drugs, and illicit steroids. Future compliance responses may include infringement notices, product seizures, import interventions, and civil or criminal penalties; advertising or promoting unapproved peptides through social media or influencer channels is likely to breach Australian therapeutic goods advertising laws. The escalation parallels the FDA's PCAC reclassification track and tightens the global regulatory squeeze on the gray-market peptide channel.
Hims & Hers' announced $1.15 billion acquisition of Eucalyptus continues to be a major catalyst for the company alongside Friday's JPMorgan Overweight upgrade. Eucalyptus brings Australia and Japan exposure, with management targeting more than $1 billion in annual international revenue within three years. Combined with the recent Eli Lilly LillyDirect partnership (Foundayo, Zepbound, KwikPen) and the FDA peptide reclassification framework, Hims now has three strategic catalysts reshaping its 2026 trajectory.
Australia's Therapeutic Goods Administration warned of rising imports of unapproved peptide products promoted on social media, citing risks including severe allergic reactions, systemic inflammatory response, infection, and organ damage. Named products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 — often supplied as injectables.